
==== Front
World J Virol
WJV
World Journal of Virology
2220-3249
Baishideng Publishing Group Inc

jWJV.v13.i3.eid96453
10.5501/wjv.v13.i3.96453
96453
Observational Study
Recurrent stroke admissions with vs without COVID-19 and associated in-hospital mortality: A United States nationwide analysis, 2020
Desai R et al. Stroke admissions with COVID-19
Desai Rupak Outcomes Research, Independent Researcher, Atlanta, GA 30033, United States

Mellacheruvu Sai Priyanka Department of Public Health, University of Massachusetts, Lowell, MA 01854, United States

Akella Sai Anusha Department of Internal Medicine, One Brooklyn Health- Interfaith Medical Center, Brooklyn, NY 11213, United States

Mohammed Adil Sarvar Department of Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI 48602, United States

Hussain Mushfequa Department of Internal Medicine, Kamineni Institute of Medical Sciences, Narketpally 508254, India

Mohammed Abdul Aziz Department of Internal Medicine, Kamineni Institute of Medical Sciences, Narketpally 508254, India. s.aadil19@gmail.com

Saketha Pakhal Department of Internal Medicine, Bhaskar Medical College, Moinabad 500075, Hyderabad, India

Sunkara Praveena Department of Internal Medicine, MedStar Medical Group, Charlotte Hall, MD 20622, United States

Gummadi Jyotsna Department of Medicine, Medstar Franklin Square Medical Center, Baltimore, MD 21237, United States

Ghantasala Paritharsh Department of Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI 48602, United States

Author contributions: Desai R and Mellacheruvu SP designed the research study; Akella SA, Mohammed AS, Hussain M, Mohammed AA, and Desai R performed the research; Akella SA, Mohammed AS, Mellacheruvu SP, Saketha P, and Sunkara P analyzed the data and wrote the manuscript; Gummadi J, Ghantasala P, and Desai R reviewed and edited the manuscript; All authors have read and approved the final manuscript.

Corresponding author: Adil Sarvar Mohammed, MD, Doctor, Department of Internal Medicine, Central Michigan University College of Medicine, 1632 Stone Street, Saginaw, MI 48602, United States. s.aadil19@gmail.com

25 9 2024
25 9 2024
13 3 964538 5 2024
12 6 2024
10 7 2024
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
BACKGROUND

Coronavirus disease 2019 (COVID-19) has been shown to increase the risk of stroke. However, the prevalence and risk of recurrent stroke in COVID-19 patients with prior stroke/transient ischemic attack (TIA), as well as its impact on mortality, are not established.

AIM

To evaluate the impact of COVID-19 on in-hospital mortality, length of stay, and healthcare costs in patients with recurrent strokes.

METHODS

We identified admissions of recurrent stroke (current acute ischemic stroke admissions with at least one prior TIA or stroke) in patients with and without COVID-19 using ICD-10-CM codes using the National Inpatient Sample (2020). We analyzed the impact of COVID-19 on mortality following recurrent stroke admissions by subgroups.

RESULTS

Of 97455 admissions with recurrent stroke, 2140 (2.2%) belonged to the COVID-19-positive group. The COVID-19-positive group had a higher prevalence of diabetes and chronic kidney disease vs the COVID-19 negative group (P < 0.001). Among the subgroups, patients aged > 65 years, patients aged 45–64 years, Asians, Hispanics, whites, and blacks in the COVID-19 positive group had higher rates of all-cause mortality than the COVID-19 negative group (P < 0.01). Higher odds of in-hospital mortality were seen in the group aged 45-64 (OR: 8.40, 95%CI: 4.18-16.91) vs the group aged > 65 (OR: 7.04, 95%CI: 5.24-9.44), males (OR: 7.82, 95%CI: 5.38-11.35) compared to females (OR: 6.15, 95%CI: 4.12-9.18), and in Hispanics (OR: 15.47, 95%CI: 7.61-31.44) and Asians/Pacific Islanders (OR: 14.93, 95%CI: 7.22-30.87) compared to blacks (OR: 5.73, 95%CI: 3.08-10.68), and whites (OR: 5.54, 95%CI: 3.79-8.09).

CONCLUSION

The study highlights the increased risk of all-cause in-hospital mortality in recurrent stroke patients with COVID-19, with a more pronounced increase in middle-aged patients, males, Hispanics, or Asians.

COVID-19
SARS-CoV-2
Recurrent stroke
Mortality
Hospitalization
Comorbidities
Acute ischemic stroke
==== Body
pmc Core Tip: This study underscores the enhanced all-cause in-hospital mortality risk among recurrent stroke patients who test positive for coronavirus disease 2019 (COVID-19). Notably, the increased mortality risk is most significant in middle-aged individuals (45-64 years), males, and ethnic minorities, including Hispanics and Asians. Data from the National Inpatient Sample in 2020 revealed that COVID-19 patients with prior stroke or transient ischemic attack exhibit higher mortality compared to non-COVID-19 counterparts, alongside a greater prevalence of comorbidities such as diabetes and chronic kidney disease. These findings emphasize the critical need for targeted management strategies in these high-risk groups.

INTRODUCTION

Stroke poses a substantial health burden, affecting around 795000 people annually in the United States and ranking as a leading cause of long-term disability. Nearly 1 in 4 of these occur in patients with a history of stroke[1] i.e., approximately 25% of all strokes are recurrent[2]. There are several preventive strategies to reduce the risk of recurrent stroke, including medication and mitigating the risk factors[3]. Despite these preventive practices, the 5-year cumulative incidence of recurrent stroke remains relatively high, ranging from 16% to 30%[4,5]. Mohan et al[4], reported the cumulative risk of recurrence after first event stroke to be 3.1% at 30 days, 11.1% at 1 year, 26.4% at 5 years, and 39.2% at 10 years. To compound this issue, the emergence of coronavirus disease 2019 (COVID-19) has introduced new challenges and is linked to an increased risk of acute ischemic stroke[6,7]. In our study, we investigated the influence of COVID-19 on in-hospital mortality rates among patients admitted for recurrent stroke, comparing those who tested positive for the virus to those who did not.

MATERIALS AND METHODS

Study design and setting

The data utilized in this investigation were obtained from the National Inpatient Sample (NIS) (2020) database, an organization sponsored by the Agency for Healthcare Research and Quality. The NIS was provided with discharge data for over 7 million hospitalizations spanning 48 states by over 1000 hospital facilities[3]. This study focused on hospitalized individuals with recurrent stroke diagnoses.

Study population and data collection

Our study population was primarily composed of recurrent stroke hospitalizations. We divided these patients into two cohorts based on their COVID-19 test results: The COVID-19 positive (+) and COVID-19 negative (-) cohorts. A recurrent stroke was defined as any new acute ischemic stroke occurring with an onset separate from that of the index stroke or transient ischemic attack history. The primary outcome was in-hospital mortality. In addition, we conducted a subgroup analysis of in-hospital mortality by age, gender, and race. We evaluated demographics and baseline characteristics.

Statistical analysis

Descriptive statistics were utilized to analyze the demographics and comorbidities of the study population. We evaluated differences in baseline characteristics between the two cohorts using χ2 tests for categorical variables and the Mann-Whitney U test for continuous variables (non-normal distribution). The in-hospital mortality was determined using multivariable logistic regression analyses adjusted for potential confounders. The results were presented as adjusted odds ratios (aORs) with 95% confidence intervals (CI).

RESULTS

We found that there were 97255 hospitalizations due to recurrent strokes in the NIS database for the year 2020. Among recurrent stroke hospitalizations, 2140 (2.2%) belonged to the COVID-19 (+) cohort, and 95115 (97.8%) belonged to the COVID-19 (-) cohort. The COVID-19 (+) cohort predominantly comprised individuals aged 65 and above, accounting for 72.9% of cases. The proportion of COVID-19 + patients was greater in males (53.5%) compared to females (46.5%). When examining ethnicity, whites constituted the majority of the COVID-19 (+) cohort at 53.2%, blacks at 25.1%, Hispanics at 17.2%, and Asian/Pacific Islanders at 4.2%. Regarding socioeconomic status, those in the lowest income percentile (0–25) had the highest representation within the COVID-19 (+) cohort at 36.5%. Among healthcare facilities, urban teaching hospitals had the highest proportion of COVID-19 (+) cases at 75%, compared to urban non-teaching hospitals at 16.6% and rural hospitals at 8.4%. Moreover, patients with comorbidities such as diabetes (53.0%) and chronic kidney disease (CKD) (30.8%) were more frequently found within the COVID-19 (+) cohort compared to the COVID-19 (-) cohort (Table 1).

Table 1 Baseline characteristics, comorbidities and outcomes of recurrent/subsequent stroke admissions with vs without coronavirus disease 2019, 2020

Variables	Total recurrent stroke (AIS with prior stroke/TIA) (n = 97255)	P value	
No COVID-19 (n = 95115), %	COVID-19 (n = 2140), %	
Age in years at admission	Median (IQR)	72 (62-82)	73 (63-82)	0.001	
    	18-44	3.6	3.7	
45-64	27.0	23.4	
≥ 65	69.4	72.9	
Sex	Male	51.0	53.5	0.023	
Female	49.0	46.5	
Race	White	68.9	53.2	< 0.001	
Black	19.3	25.1	
Hispanic	8.6	17.2	
Asian/Pacific Islander	2.8	4.2	
Native American	0.4		
Median household income national quartile for patient ZIP code	0-25th	31.3	36.5	< 0.001	
26-50th	27.1	30.1	
51-75th	23.1	18.0	
76-100th	18.4	15.4	
Payer type	Medicare	72.8	74.6	0.118	
Medicaid	10.2	9.0	
Private	17.0	16.4	
Hospital location & teaching status	Rural	6.7	8.4	0.001	
Urban Nonteaching	18.6	16.6	
Urban Teaching	74.7	75.0	
Hospital region	Northeast	14.5	16.8	< 0.001	
Midwest	21.1	19.2	
South	45.2	47.9	
West	19.2	16.1	
Comorbidities	
    Hypertension		89.5	85.7	< 0.001	
    Diabetes		43.2	53.0	< 0.001	
    Hyperlipidemia		66.8	61.4	< 0.001	
    Obesity		14.9	16.1	0.124	
    Peripheral vascular disease		11.7	8.6	< 0.001	
    Tobacco use disorder		28.9	28.3	0.535	
    Prior MI		10.3	5.8	< 0.001	
    Prior VTE		5.6	6.3	0.162	
    Cancer		5.0	3.7	0.009	
    Chronic kidney disease		22.7	30.8	< 0.001	
    Alcohol abuse		4.3	2.8	0.001	
    Drug abuse		3.1	2.1	0.007	
    Depression		11.8	9.6	0.001	
    Chronic pulmonary disease		17.3	15.0	0.004	
    Hypothyroidism		15.2	14.0	0.133	
    Other thyroid disorders		2.3	2.1	0.502	
    Valvular disease		2.7	1.6	0.002	
    Autoimmune conditions		3.2	2.8	0.283	
Outcomes	
    All-cause in-hospital mortality		4.0	22.9	< 0.001	
    Disposition of patient	Routine	36.6	25.2	< 0.001	
Transfer to short-term hospital	2.8	3.4	
Transfer other: SNF, ICF, etc.	38.6	49.7	
Home health care	21.9	21.8	
    Length of stay (days)	Median (IQR)	3 (2-6)	7 (3-13)	< 0.001	
    Hospital charges (USD)	Median	$52662	$80888	< 0.001	
P < 0.05 is noted to be statistically significant. MI: Myocardial infarction; VTE: Venous thromboembolism; SNF: Skilled nursing facility; ICF: Intermediate care facility; IQR: Inter-quartile range; TIA: Transient ischemic attack; COVID-19: Coronavirus disease 2019.

Patients in the COVID-19 (+) cohort showed poorer outcomes, with 49.7% requiring disposition to facilities like skilled nursing facility, intermediate care facility, etc., and 21.8% requiring home health care. The median length of stay was higher (7 days) for the COVID-19 (+) cohort compared to COVID-19 (-) (3 days). The median cost of hospitalization was also higher among the COVID-19 (+) cohort ($80888) compared to patients without COVID-19 ($52662) (all P-values < 0.005) (Table 1). Unadjusted all-cause mortality was substantially higher among recurrent stroke patients who belonged to the COVID-19 (+) cohort compared to COVID-19 (-) (22.9% vs 4.0%) (Table 1).

Using multivariate regression after adjusting for all factors and covariates, our analyses showed high in-hospital mortality among recurrent stroke patients with COVID-19 (+) (aOR: 7.01, 95%CI: 5.36–9.18). Subgroup analyses revealed higher odds among patients aged 45-64 (aOR: 8.4, 95%CI: 4.18-16.91) compared to age group 65 or greater (aOR: 7.04, 95%CI: 5.24-9.44); among males (aOR: 7.82, 95%CI: 5.38-11.35) compared to females (aOR: 6.15, 95%CI: 4.12-9.18). Although patients of all races exhibited significant adjusted odds of in-hospital mortality, Hispanics (aOR: 15.47, 95%CI: 7.61-31.44) and Asian Pacific Islanders (aOR: 14.93, 95%CI: 7.22-30.87) had almost three times more odds than Blacks (aOR: 5.73, 95%CI: 3.08-10.68), and White population (aOR: 5.54, 95%CI: 3.79-8.09) (All P value < 0.005) (Table 2).

Table 2 Multivariable logistic regression assessing impact of coronavirus disease 2019 on mortality following recurrent stroke admissions

In-hospital mortality	COVID-19	Adjusted OR	95%CI	P value	
Lower Limit	Upper limit	
Overall mortality	Yes vs No	7.01	5.36	9.18	< 0.001	
In-hospital mortality by individual subgroup	
Ages 45-64	Yes vs No	8.4	4.18	16.91	< 0.001	
Ages 65 and above	Yes vs No	7.04	5.24	9.44	< 0.001	
Male	Yes vs No	7.82	5.38	11.35	< 0.001	
Female	Yes vs No	6.15	4.12	9.18	< 0.001	
Whites	Yes vs No	5.54	3.79	8.09	< 0.001	
Blacks	Yes vs No	5.73	3.08	10.68	< 0.001	
Hispanics	Yes vs No	15.47	7.61	31.44	< 0.001	
Asian/Pacific Islanders	Yes vs No	14.93	7.22	30.87	< 0.001	
P < 0.05 indicates statistical significance. Multivariable regression models were adjusted for baseline demographics, hospital level characteristics and relevant comorbidities. COVID-19: Coronavirus disease 2019; OR: Odds ratio.

DISCUSSION

Hospitalizations for recurrent strokes in patients who also tested positive for COVID-19 were associated with higher mortality rates longer stays in the hospital and increased total healthcare costs. Within the COVID-19 (+) cohort, it was observed that men, individuals in middle age, as well as Hispanic and Asian patients, faced a greater risk of in-hospital mortality.

Our findings align with other studies indicating a significant increase in risk-associated deaths from heart disease and stroke among COVID-19 patients, particularly among ethnic and racial minorities[8]. The heightened mortality risk is intricately linked to the interplay between inflammation and endothelial dysfunction induced by COVID-19. Severe cases trigger a cytokine storm, leading to endothelial injury and thrombotic complications. The study by Lee et al[9]. further elucidates how COVID-19 antibody-mediated cytotoxicity against endothelial cells initiates vascular complications, exacerbating damage in patients with recurrent stroke. The severe stroke presentations in COVID-19 (+) patients[10] can be attributed to COVID-19-induced inflammation and immune dysregulation. Additionally, decreased emergency department visits and delayed hospital admissions due to the pandemic contributed to poor outcomes[11].

While our study revealed that most patients admitted with recurrent acute ischemic stroke and COVID-19 were in the older age group (> 60 years), the adjusted odds for in-hospital mortality were higher across all age groups. Interestingly, the middle-aged group exhibited higher odds compared to other age groups. These results are consistent with findings in other studies that suggested older adults were better protected due to fewer contacts with exposure. For instance, Malmgren et al[12] in Washington State reported a decline in COVID-19 among older individuals and an increase in younger patients, speculating that public warnings targeted those aged 60 and older. In contrast, younger adults had more social interactions. This finding also aligns with studies that hypothesized older adults were better protected[13]. Possible explanations for poorer outcomes in middle-aged include that they may have more subclinical chronic conditions like undiagnosed hypertension and poor metabolic health, leading to worse COVID-19 outcomes[14,15], and this age group may also have a dysregulated immune response leading to increased mortality[16].

Ethnic and racial disparities were evident, with Hispanics and Asian Pacific Islanders showing alarmingly higher odds of mortality. These results align with existing literature highlighting the disproportionate impact of COVID-19 on minority racial and ethnic groups, with hospitalizations being highest among Hispanic/Latino patients[17]. A multicenter case-control study conducted in England and Scotland during the first wave of the pandemic found that Asian ethnicity is strongly linked to COVID-19-related stroke, with the proportion of cases among Asians being more than twice the controls[18]. Annual United States mortality study of 2020 COVID-19-related deaths investigating the impact of socioeconomic position showed that low socioeconomic position and Hispanic ethnicity also stand out as risk factors for COVID-19-related mortality[19,20].

Adjusted subgroup analysis also showed that males had higher in-hospital mortality compared to females. Existing literature shows that there is a more significant burden of stroke deaths among women[21]. However, our study findings showed increased mortality in men compared to women. This finding could have resulted from poorer outcomes from COVID-19 disease among men. These worse outcomes among men suffering from COVID-19 could be attributed to inherent immune differences, an increased prevalence of unhealthy behaviors such as smoking and consuming alcohol, and a higher prevalence of metabolic risk factors among men[22-24].

Our study revealed an elevated prevalence of diabetes and CKD among patients with recurrent stroke and COVID-19. This finding can be attributed to the immunosuppressed nature of these conditions[25]. Diabetic and CKD patients exhibit worsened outcomes due to COVID-19 disease, including higher hospitalization rates, severe pneumonia, acute respiratory distress syndrome, the need for dialysis, and increased mortality[26,27]. Persistent hyperglycemia in diabetes hinders the immune response due to the pro-inflammatory state induced by elevated levels of inflammatory markers such as interleukin-6 and C-reactive protein, aggravating worse clinical outcomes[28]. Concurrently, CKD patients face increased thrombotic risk due to chronic inflammation and uremia[29]. Hypertension, a significant COVID-19 risk factor[30,31], predisposes infected individuals to severe disease through endothelial dysfunction-mediated hypercoagulability[32]. Exploring the impact of the COVID-19 pandemic on the management of chronic conditions reveals a pandemic-induced decline in doctor visits, particularly affecting vulnerable populations[33]. This decline exacerbates comorbidities, raising the risk of recurrent stroke as medication adherence and healthcare continuity wane[34,35]. Our study also highlights the increased risk of recurrent stroke among obese patients, consistent with current literature[36,37]. The pandemic-driven rise in average BMI and obesity prevalence, potentially stemming from decreased physical activity and a sedentary lifestyle, adds to the multifaceted challenges posed by COVID-19[38,39].

Recurrent stroke poses a significant burden on both patients and the healthcare system, with mortality ranging from 11.6% to 25.9% for in-hospital 30-day or 4-year periods[10]. Disability-adjusted life years (DALY) analysis by Hong et al[40] indicates a DALY loss of 3.82 after the index stroke, with an additional 0.84 DALY lost due to recurrent stroke. The average healthcare cost per person for stroke, including inpatient care, rehabilitation, and follow-up, is estimated at USD 140048[41]. Our study reports median in-hospital costs for recurrent stroke and COVID-19 at $80888, $28226 higher than those without COVID-19. Patients in the COVID-19 (+) cohort had a longer length of stay at seven days compared to those in the COVID-19 (-) cohort (3 days).

Clinical implications

Given this significant burden, our study has many future clinical implications. Rigorous management of risk factors and comorbid conditions is necessary. Timely screening, healthy behaviors, and equitable healthcare access are pivotal in reducing the disparities found in our study. Telemedicine and tailored prevention plans are crucial for achieving continuity of care and must be further explored for less severe cases.

Limitations

Through this study, we highlighted various risk factors for poor outcomes in patients admitted due to recurrent stroke and COVID-19. However, it is imperative to acknowledge the retrospective nature of our study and its inherent limitations. The observational nature of the study limits control over all potential confounders. Firstly, there might be administrative coding errors in the NIS database, which could over or underestimate COVID-19 and recurrent strokes. Variability in documentation and coding of comorbidities and outcomes across different healthcare facilities could influence the results. Secondly, our study only focuses on data from hospitalized patients, introducing potential sampling bias, as it overlooks undiagnosed or milder cases of COVID-19 not requiring hospitalization. Lack of outpatient data and long-term COVID-19 symptoms monitoring might impact results. An additional constraint of our study, stemming from its reliance on the NIS database for 2020, is the absence of vaccination status data for the subjects early in the pandemic. This limitation is particularly critical when assessing the potential mitigating impact of COVID-19 vaccines on the severe presentation of stroke, as demonstrated by Jiang et al[42], who found an association between even partial vaccination and a lower risk of major adverse cardiovascular events post-COVID-19 infection. Thirdly, data on the incidence of stroke among various ethnicities could have been influenced by reporting bias, as previous studies have shown a higher risk of stroke among African Americans. Finally, the data was not subclassified based on mechanisms of previous stroke, such as large vessel atherosclerosis or cardioembolic stroke. This subclassification is crucial for determining outcomes based on underlying mechanisms, and future prospective studies need to focus on incorporating this data to improve the management of these patients. In this context, future studies should focus on these limitations, and further prospective studies should be done with vaccination status data to understand the efficacy of vaccines in preventing severe manifestations and improving vaccination rates. Also, studies need to be done to understand the long-term implications of COVID-19 disease on patients with a history of stroke or TIA.

CONCLUSION

Our study shows increased in-hospital mortality after recurrent stroke and COVID-19, especially among the age group 45–64 years, Hispanics, and males. Given these findings, it is imperative to monitor risk factors such as diabetes rigorously, consistently screen them with HbA1c tests, and maintain strict glucose control, as such patients are at significant risk for recurrent stroke. Ensuring these patients stay compliant with secondary prevention strategies such as statin and antiplatelet agent use is paramount. Ethnic disparities evident in our study might be due to the lack of access and increased disease burden in these minority populations. Possible ways to reduce disparities include implementing evidence-based practices system-wide with quality improvement initiatives and encouraging best practices. New policies must address these disparities and reinforce existing policies to improve health equity among all ethnicities. Further prospective studies are essential to unraveling the mechanisms underlying the long-term consequences of COVID-19, particularly stroke incidence. Designing a comprehensive timeline for stroke occurrences and post-Covid-19 infection will contribute to a deeper understanding of this phenomenon. As more data on the long-term sequelae of COVID-19 evolves, the risk of stroke and other thromboembolic phenomena could be better understood.

Data sharing statement

Not applicable.

Institutional review board statement: Since the data included in this review were de-identified and already available in publicly accessible databases, the IRB review was not mandatory. This review was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent statement: No written consent has been obtained from the patients, as no patient-identifiable data from the NIS database is included in this observational study.

Conflict-of-interest statement: All authors declare no conflict of interest.

STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Infectious diseases

Country of origin: United States

Peer-review report’s classification

Scientific Quality: Grade B

Novelty: Grade B

Creativity or Innovation: Grade B

Scientific Significance: Grade B

P-Reviewer: Vyshka G S-Editor: Liu JH L-Editor: A P-Editor: Zheng XM
==== Refs
1 Tsao CW Aday AW Almarzooq ZI Anderson CAM Arora P Avery CL Baker-Smith CM Beaton AZ Boehme AK Buxton AE Commodore-Mensah Y Elkind MSV Evenson KR Eze-Nliam C Fugar S Generoso G Heard DG Hiremath S Ho JE Kalani R Kazi DS Ko D Levine DA Liu J Ma J Magnani JW Michos ED Mussolino ME Navaneethan SD Parikh NI Poudel R Rezk-Hanna M Roth GA Shah NS St-Onge MP Thacker EL Virani SS Voeks JH Wang NY Wong ND Wong SS Yaffe K Martin SS American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association Circulation 2023 147 e93 e621 36695182
2 Modig K Talbäck M Ziegler L Ahlbom A Temporal trends in incidence, recurrence and prevalence of stroke in an era of ageing populations, a longitudinal study of the total Swedish population BMC Geriatr 2019 19 31 30717697
3 Kleindorfer DO Towfighi A Chaturvedi S Cockroft KM Gutierrez J Lombardi-Hill D Kamel H Kernan WN Kittner SJ Leira EC Lennon O Meschia JF Nguyen TN Pollak PM Santangeli P Sharrief AZ Smith SC Jr Turan TN Williams LS 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association Stroke 2021 52 e364 e467 34024117
4 Mohan KM Wolfe CD Rudd AG Heuschmann PU Kolominsky-Rabas PL Grieve AP Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis Stroke 2011 42 1489 1494 21454819
5 Kolominsky-Rabas PL Weber M Gefeller O Neundoerfer B Heuschmann PU Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study Stroke 2001 32 2735 2740 11739965
6 Ntaios G Michel P Georgiopoulos G Guo Y Li W Xiong J Calleja P Ostos F González-Ortega G Fuentes B Alonso de Leciñana M Díez-Tejedor E García-Madrona S Masjuan J DeFelipe A Turc G Gonçalves B Domigo V Dan GA Vezeteu R Christensen H Christensen LM Meden P Hajdarevic L Rodriguez-Lopez A Díaz-Otero F García-Pastor A Gil-Nuñez A Maslias E Strambo D Werring DJ Chandratheva A Benjamin L Simister R Perry R Beyrouti R Jabbour P Sweid A Tjoumakaris S Cuadrado-Godia E Campello AR Roquer J Moreira T Mazya MV Bandini F Matz K Iversen HK González-Duarte A Tiu C Ferrari J Vosko MR Salzer HJF Lamprecht B Dünser MW Cereda CW Quintero ÁBC Korompoki E Soriano-Navarro E Soto-Ramírez LE Castañeda-Méndez PF Bay-Sansores D Arauz A Cano-Nigenda V Kristoffersen ES Tiainen M Strbian D Putaala J Lip GYH Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry Stroke 2020 51 e254 e258 32787707
7 Merkler AE Parikh NS Mir S Gupta A Kamel H Lin E Lantos J Schenck EJ Goyal P Bruce SS Kahan J Lansdale KN LeMoss NM Murthy SB Stieg PE Fink ME Iadecola C Segal AZ Cusick M Campion TR Jr Diaz I Zhang C Navi BB Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza JAMA Neurol 2020 77 1 7 32614385
8 Sidney S Lee C Liu J Khan SS Lloyd-Jones DM Rana JS Age-Adjusted Mortality Rates and Age and Risk-Associated Contributions to Change in Heart Disease and Stroke Mortality, 2011-2019 and 2019-2020 JAMA Netw Open 2022 5 e223872 35319764
9 Lee MH Perl DP Steiner J Pasternack N Li W Maric D Safavi F Horkayne-Szakaly I Jones R Stram MN Moncur JT Hefti M Folkerth RD Nath A Neurovascular injury with complement activation and inflammation in COVID-19 Brain 2022 145 2555 2568 35788639
10 Ferrone SR Sanmartin MX Ohara J Jimenez JC Feizullayeva C Lodato Z Shahsavarani S Lacher G Demissie S Vialet JM White TG Wang JJ Katz JM Sanelli PC Acute ischemic stroke outcomes in patients with COVID-19: a systematic review and meta-analysis J Neurointerv Surg 2024 16 333 341 37460215
11 Tong X King SMC Asaithambi G Odom E Yang Q Yin X Merritt RK COVID-19 Pandemic and Quality of Care and Outcomes of Acute Stroke Hospitalizations: the Paul Coverdell National Acute Stroke Program Prev Chronic Dis 2021 18 E82 34410906
12 Malmgren J Guo B Kaplan HG Continued proportional age shift of confirmed positive COVID-19 incidence over time to children and young adults: Washington State March-August 2020 PLoS One 2021 16 e0243042 33760808
13 O'Driscoll M Ribeiro Dos Santos G Wang L Cummings DAT Azman AS Paireau J Fontanet A Cauchemez S Salje H Age-specific mortality and immunity patterns of SARS-CoV-2 Nature 2021 590 140 145 33137809
14 Elias S Dadi TK Prevalence of Undiagnosed Hypertension and Associated Factors among Adults in Mizan-Aman Town, Bench Sheko Zone, Southwest Ethiopia: A Community-Based Cross-Sectional Study Adv Med 2023 2023 2746284 37469806
15 Boro B Banerjee S Decomposing the rural-urban gap in the prevalence of undiagnosed, untreated and under-treated hypertension among older adults in India BMC Public Health 2022 22 1310 35799143
16 Bartleson JM Radenkovic D Covarrubias AJ Furman D Winer DA Verdin E SARS-CoV-2, COVID-19 and the Ageing Immune System Nat Aging 2021 1 769 782 34746804
17 Romano SD Blackstock AJ Taylor EV El Burai Felix S Adjei S Singleton CM Fuld J Bruce BB Boehmer TK Trends in Racial and Ethnic Disparities in COVID-19 Hospitalizations, by Region - United States, March-December 2020 MMWR Morb Mortal Wkly Rep 2021 70 560 565 33857068
18 Perry RJ Smith CJ Roffe C Simister R Narayanamoorthi S Marigold R Willmot M Dixit A Hassan A Quinn TJ Ankolekar S Zhang L Banerjee S Ahmed U Padmanabhan N Ferdinand P McGrane F Banaras A Marks IH Werring DJ SETICOS collaborators Characteristics and outcomes of COVID-19 associated stroke: a UK multicentre case-control study J Neurol Neurosurg Psychiatry 2021 92 242 248 33154179
19 Pathak EB Menard JM Garcia RB Salemi JL Joint Effects of Socioeconomic Position, Race/Ethnicity, and Gender on COVID-19 Mortality among Working-Age Adults in the United States Int J Environ Res Public Health 2022 19
20 Robinson DJ Stanton R Sucharew H Alwell K Haverbusch M De Los Rios La Rosa F Ferioli S Coleman E Jasne A Mackey J Star M Mistry EA Demel S Slavin S Walsh K Woo D Kissela B Kleindorfer DO Racial Disparities in Stroke Recurrence: A Population-Based Study Neurology 2022 99 e2464 e2473 36041865
21 Rexrode KM Madsen TE Yu AYX Carcel C Lichtman JH Miller EC The Impact of Sex and Gender on Stroke Circ Res 2022 130 512 528 35175851
22 Fabião J Sassi B Pedrollo EF Gerchman F Kramer CK Leitão CB Pinto LC Why do men have worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age Braz J Med Biol Res 2022 55 e11711 35195196
23 Shim E Tariq A Choi W Lee Y Chowell G Transmission potential and severity of COVID-19 in South Korea Int J Infect Dis 2020 93 339 344 32198088
24 Manaf MRA Nawi AM Tauhid NM Othman H Rahman MRA Yusoff HM Safian N Ng PY Manaf ZA Kadir NBA Yanasegaran K Basir SMA Ramakrishnappa S Ganasegeran K Prevalence of metabolic syndrome and its associated risk factors among staffs in a Malaysian public university Sci Rep 2021 11 8132 33854087
25 Pecly IMD Azevedo RB Muxfeldt ES Botelho BG Albuquerque GG Diniz PHP Silva R Rodrigues CIS COVID-19 and chronic kidney disease: a comprehensive review J Bras Nefrol 2021 43 383 399 33836039
26 Chung EYM Palmer SC Natale P Krishnan A Cooper TE Saglimbene VM Ruospo M Au E Jayanti S Liang A Jie Deng DJ Chui J Higgins GY Tong A Wong G Teixeira-Pinto A Hodson EM Craig JC Strippoli GFM Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis Am J Kidney Dis 2021 78 804 815 34364906
27 Singh AK Khunti K COVID-19 and Diabetes Annu Rev Med 2022 73 129 147 34379444
28 Lima-Martínez MM Carrera Boada C Madera-Silva MD Marín W Contreras M COVID-19 and diabetes: A bidirectional relationship Clin Investig Arterioscler 2021 33 151 157
29 Kelly DM Ademi Z Doehner W Lip GYH Mark P Toyoda K Wong CX Sarnak M Cheung M Herzog CA Johansen KL Reinecke H Sood MM Chronic Kidney Disease and Cerebrovascular Disease: Consensus and Guidance From a KDIGO Controversies Conference Stroke 2021 52 e328 e346 34078109
30 Muhamad SA Ugusman A Kumar J Skiba D Hamid AA Aminuddin A COVID-19 and Hypertension: The What, the Why, and the How Front Physiol 2021 12 665064 34012410
31 Konukoglu D Uzun H Endothelial Dysfunction and Hypertension Adv Exp Med Biol 2017 956 511 540 28035582
32 Spiezia L Boscolo A Poletto F Cerruti L Tiberio I Campello E Navalesi P Simioni P COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure Thromb Haemost 2020 120 998 1000 32316063
33 Czeisler MÉ Marynak K Clarke KEN Salah Z Shakya I Thierry JM Ali N McMillan H Wiley JF Weaver MD Czeisler CA Rajaratnam SMW Howard ME Delay or Avoidance of Medical Care Because of COVID-19-Related Concerns - United States, June 2020 MMWR Morb Mortal Wkly Rep 2020 69 1250 1257 32915166
34 Egan BM Sutherland SE Macri CI Deng Y Gerelchuluun A Rakotz MK Campbell SV Association of Baseline Adherence to Antihypertensive Medications With Adherence After Shelter-in-Place Guidance for COVID-19 Among US Adults JAMA Netw Open 2022 5 e2247787 36538326
35 Kronish IM Diefenbach MA Edmondson DE Phillips LA Fei K Horowitz CR Key barriers to medication adherence in survivors of strokes and transient ischemic attacks J Gen Intern Med 2013 28 675 682 23288379
36 Modin D Claggett B Sindet-Pedersen C Lassen MCH Skaarup KG Jensen JUS Fralick M Schou M Lamberts M Gerds T Fosbøl EL Phelps M Kragholm KH Andersen MP Køber L Torp-Pedersen C Solomon SD Gislason G Biering-Sørensen T Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction Circulation 2020 142 2080 2082 33054349
37 Horn JW Feng T Mørkedal B Strand LB Horn J Mukamal K Janszky I Obesity and Risk for First Ischemic Stroke Depends on Metabolic Syndrome: The HUNT Study Stroke 2021 52 3555 3561 34281375
38 Restrepo BJ Obesity Prevalence Among U.S. Adults During the COVID-19 Pandemic Am J Prev Med 2022 63 102 106 35725124
39 Joundi RA Patten SB Williams JVA Smith EE Association Between Excess Leisure Sedentary Time and Risk of Stroke in Young Individuals Stroke 2021 52 3562 3568 34407638
40 Hong KS Saver JL Kang DW Bae HJ Yu KH Koo J Han MK Cho YJ Park JM Lee BC Years of optimum health lost due to complications after acute ischemic stroke: disability-adjusted life-years analysis Stroke 2010 41 1758 1765 20595674
41 Johnson BH Bonafede MM Watson C Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke Clinicoecon Outcomes Res 2016 8 53 61 26966382
42 Jiang J Chan L Kauffman J Narula J Charney AW Oh W Nadkarni G N3C Consortium Impact of Vaccination on Major Adverse Cardiovascular Events in Patients With COVID-19 Infection J Am Coll Cardiol 2023 81 928 930 36813689
